A bit over 5,000 shares exchanging hands, 12k on the next day, over 700k during the one after that – this is what happened with Accentia Biopharmaceuticals Inc. (PINK:ABPI) in the last three days of the week. The most probable catalyst behind that – another pink sheet enterprise. 
Naturally, when such an amount of shares is traded there is an effect on the price, as well. Not what you would expect though – just a 5.5% increase on Friday, the session closing $0.45 per share. As mentioned, what most probably caused the hype was a press release from Sep. 29th about a subsidiary of Accentia. A subsidiary with a product that was featured as a cover story in HemOnc Today.
In the meantime, shorters also had a busy last day of the week. It was a total of 711k shares traded on Friday, but 150k were due to short-selling activity. Still, it has been almost a year since similar trading activity took place for Accentia. What is more, an all-time low of the stock price was reached in August. A possible reason for that – the balance sheet. It was in August that the second quarterly statement for 2011 came out. It includes the following, among other figures:
- $1.3 million in cash; [BANNER]
- $3.6 million in total current assets;
- $22.9 million in total current liabilities;
- $331 million in accumulated deficit;
- $2 million in revenues;
- $3.7 million in net loss;
Not exactly inspiring, which is why the stock performance could be qualified as sustainable growth. In terms, there are the possibilities for short profits, but there is also the high level of risk involved.
